Presented Final Data from Phase 1b/2 Trial of AU-011 in Choroidal Melanoma at the American Academy of Ophthalmology’s Annual Meeting Completed Initial Public Offering to Fund Pivotal Program for AU-011 in Choroidal Melanoma and Earlier Stage Oncology Pipeline CAMBRIDGE, Mass.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 23, 2021-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications including ocular and urologic cancers, today announced that

Presentations Include Final Safety and Efficacy Data from the Phase 1b/2 Trial using Intravitreal Administration and Updated Safety Data from the Phase 2 Trial using Suprachoroidal Administration CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 15, 2021-- Aura Biosciences , a clinical-stage oncology

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 28, 2021-- Aura Biosciences, Inc. (“Aura”), a clinical-stage oncology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced the pricing of its initial public offering of 5,400,000 shares of

CAMBRIDGE, MA – October 11, 2021  – Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the presentation of interim Phase 2 data with 7 months average follow up evaluating the

Chris Primiano, J.D., Appointed as Chief Business Officer Antony Mattessich Appointed to the Board of Directors CAMBRIDGE, MA – September 29, 2021  – Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology

Prominent, Multi-Disciplinary Clinicians and Scientists Bring Extensive Strategic Expertise in Urologic Oncology Across All Stages of Research and Development CAMBRIDGE, MA – June 17, 2021  – Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate

CAMBRIDGE, MA – June 8, 2021  – Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the appointment of Sapna Srivastava, Ph.D., to its Board of Directors.

AU-011 Demonstrates Targeted Cytotoxicity In Vitro and In Vivo in Both Breast and Lung Tumors, Demonstrating the Potential to Treat Human Choroidal Metastases Tumor Distribution of AU-011 in the Treatment of Choroidal Melanoma Also Presented Using Intravitreal and Suprachoroidal Administration

Results Support VDCs induction of Pro Immunogenic Cell Death and the Generation of Long Lasting Adaptive Anti-Tumor Immunity – Combination of VDCs with Checkpoint Inhibitors Achieves a High Complete Response Rate and Prevents Long Term Tumor Recurrence – CAMBRIDGE, MA – April 14, 2021  – Aura